Autosomal dominant hypocalcemia: genes and variants
Explore variant evidence for Autosomal dominant hypocalcemia across 2 analyzed proteins (CASR, GNA11). Linked ClinVar records include 75 pathogenic or likely pathogenic variants, 1,042 variants of uncertain significance and 121 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Autosomal dominant hypocalcemia
CASR: Extracellular calcium-sensing receptor
It senses extracellular calcium in the parathyroid gland and kidney and adjusts parathyroid-hormone secretion and renal calcium handling accordingly. Loss-of-function variants cause familial hypocalciuric hypercalcemia or neonatal severe hyperparathyroidism, whereas activating variants cause autosomal dominant hypocalcemia.
69 ClinVar pathogenic / likely pathogenic and 1,152 uncertain variants in CASR have source records linked to Autosomal dominant hypocalcemia. Association strength is not clinical gene validity.
GNA11: Guanine nucleotide-binding protein subunit alpha-11
It transmits signals from Gq-coupled receptors to phospholipase C and downstream calcium and protein-kinase-C pathways. Germline activating variants can cause autosomal dominant hypocalcemia, while somatic activating variants drive uveal melanoma and some vascular lesions.
6 ClinVar pathogenic / likely pathogenic and 11 uncertain variants in GNA11 have source records linked to Autosomal dominant hypocalcemia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Autosomal dominant hypocalcemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CASR G143E | 143 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R220W | 220 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR C582S | 582 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★★) |
| CASR F788C | 788 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR M1T | 1 | Pathogenic / likely pathogenic (★★) | |
| CASR R66H | 66 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R66C | 66 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR G143R | 143 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R220Q | 220 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR P221L | 221 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR M1V | 1 | Pathogenic / likely pathogenic (★★) | |
| CASR R185Q | 185 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR D190G | 190 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR Y218C | 218 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR Q459R | 459 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR C582Y | 582 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★★) |
| CASR R69H | 69 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR L125P | 125 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR E127A | 127 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR F128L | 128 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R172G | 172 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR D217Y | 217 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR I555T | 555 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★★) |
| CASR P55L | 55 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR C395R | 395 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR G509R | 509 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR E604K | 604 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★★) |
| CASR G613E | 613 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR G670R | 670 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR R680C | 680 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR V728F | 728 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR E767K | 767 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR R795W | 795 | Intracellular loop 3 (ICL3) | Pathogenic / likely pathogenic (★★) |
| CASR P798L | 798 | Intracellular loop 3 (ICL3) | Pathogenic / likely pathogenic (★★) |
| CASR M811V | 811 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR F832S | 832 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GNA11 R60C | 60 | G-alpha | Pathogenic / likely pathogenic (★★) |
| CASR S53P | 53 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR T151M | 151 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R465Q | 465 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CASR V817I | 817 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CASR R886W | 886 | Interaction with RNF19A | Pathogenic / likely pathogenic (★★) |
| CASR N178D | 178 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★★) |
| CASR R227Q | 227 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★★) |
| CASR N802S | 802 | Intracellular loop 3 (ICL3) | Pathogenic / likely pathogenic (★★) |
| CASR M1R | 1 | Pathogenic / likely pathogenic (★) | |
| CASR R220P | 220 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★) |
| CASR P221S | 221 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★) |
| CASR G549R | 549 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★) |
| CASR C562F | 562 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★) |
| GNA11 T54M | 54 | G-alpha | Pathogenic / likely pathogenic (★) |
| CASR R551K | 551 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★) |
| CASR G557E | 557 | Cysteine-rich (CR) | Pathogenic / likely pathogenic (★) |
| CASR F788L | 788 | Transmembrane | Pathogenic / likely pathogenic (★) |
| CASR Y95C | 95 | Ligand-binding 1 (LB1) | Pathogenic / likely pathogenic (★) |
| CASR E297K | 297 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★) |
| CASR I839N | 839 | Transmembrane | Pathogenic / likely pathogenic (★) |
| CASR A843E | 843 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GNA11 R183P | 183 | G-alpha | Pathogenic / likely pathogenic (★) |
| CASR E191K | 191 | Ligand-binding 2 (LB2) | Pathogenic / likely pathogenic (★) |
Showing 60 of 75.
Uncertain variants prioritized for review in Autosomal dominant hypocalcemia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CASR Y218H | 218 | Ligand-binding 2 (LB2) | Conflicting reports (★) | +7: 7 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.891 |
| CASR R795P | 795 | Intracellular loop 3 (ICL3) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; R795W at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.916 |
| CASR G549E | 549 | Cysteine-rich (CR) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; G549R at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.911 |
| CASR C582R | 582 | Cysteine-rich (CR) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; C582Y at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.968 |
| CASR R795Q | 795 | Intracellular loop 3 (ICL3) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; R795W at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.852 |
| CASR F788S | 788 | Transmembrane | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; F788C at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.941 |
| CASR P798R | 798 | Intracellular loop 3 (ICL3) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; P798L at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.911 |
| CASR G509A | 509 | Extracellular | Uncertain (★) | +7: G509R at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.932 |
| CASR G613R | 613 | Transmembrane | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; G613E at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.851 |
| CASR G557W | 557 | Cysteine-rich (CR) | Uncertain (★) | +7: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.882 |
| CASR D190N | 190 | Ligand-binding 2 (LB2) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; D190G at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.819 |
| CASR V817L | 817 | Transmembrane | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; V817I at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.776 |
| CASR Y218N | 218 | Ligand-binding 2 (LB2) | Uncertain (★) | +7: 7 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.841 |
| CASR P55S | 55 | Ligand-binding 1 (LB1) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; P55L at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.833 |
| CASR V728L | 728 | Transmembrane | Uncertain (★★) | +7: 2 other pathogenic changes within 3 positions; V728F at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.839 |
| CASR R795G | 795 | Intracellular loop 3 (ICL3) | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; R795W at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.908 |
| CASR R69C | 69 | Ligand-binding 1 (LB1) | Uncertain (★★) | +7: 3 other pathogenic changes within 3 positions; R69H at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.790 |
| CASR D217G | 217 | Ligand-binding 2 (LB2) | Uncertain (★★) | +7: 5 other pathogenic changes within 3 positions; D217Y at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.804 |
| CASR G557R | 557 | Cysteine-rich (CR) | Uncertain (★) | +7: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.805 |
| CASR S810T | 810 | Transmembrane | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; S810N at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.700 |
| CASR R66L | 66 | Ligand-binding 1 (LB1) | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; R66H at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.733 |
| CASR I554F | 554 | Cysteine-rich (CR) | Uncertain (★★) | +6: 4 other pathogenic changes within 3 positions; I554T at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.737 |
| CASR V728I | 728 | Transmembrane | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; V728F at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.664 |
| CASR P221Q | 221 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 6 other pathogenic changes within 3 positions; P221L at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.666 |
Which prediction tools work for Autosomal dominant hypocalcemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 98 out of 100
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 97 out of 100
- MetaSVM: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- VARITY: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 89 out of 100
- SIFT: 88 out of 100
- phyloP: 88 out of 100
- phastCons: 71 out of 100
- SpliceAI: 65 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 46 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Familial hypocalciuric hypercalcemia also has ClinVar records linked to CASR variants; they fall partly in the same places as the Autosomal dominant hypocalcemia variants (81 pathogenic / likely pathogenic).
- Nephrolithiasis/nephrocalcinosis also has ClinVar records linked to CASR variants; they fall in the same places as the Autosomal dominant hypocalcemia variants (14 pathogenic / likely pathogenic).
- Neonatal severe primary hyperparathyroidism also has ClinVar records linked to CASR variants; they fall in the same places as the Autosomal dominant hypocalcemia variants (11 pathogenic / likely pathogenic).
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia also has ClinVar records linked to CASR variants; they fall partly in the same places as the Autosomal dominant hypocalcemia variants (5 pathogenic / likely pathogenic).
Diseases related to Autosomal dominant hypocalcemia
- Familial hypocalciuric hypercalcemia, also linked to CASR and GNA11
- Familial hypoparathyroidism, also linked to CASR and GNA11
- Hypertrophic cardiomyopathy, also linked to CASR
- Idiopathic generalized epilepsy, also linked to CASR
- Nephrolithiasis/nephrocalcinosis, also linked to CASR
- Neonatal severe primary hyperparathyroidism, also linked to CASR
- Vascular malformation, also linked to GNA11
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia, also linked to CASR
- Parathyroid carcinoma, also linked to CASR
- Familial multiple nevi flammei, also linked to GNA11
Frequently asked questions
Which genes have records linked to Autosomal dominant hypocalcemia?
This view contains 2 analyzed proteins: CASR, GNA11. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 75 pathogenic or likely pathogenic variants, 1,042 variants of uncertain significance and 121 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 24 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,260 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center